4-Hydroxycyclophosphamide is a chemical compound that belongs to the class of alkylating agents, primarily used in cancer chemotherapy. It is a derivative of cyclophosphamide, which is a prodrug that requires metabolic activation. The compound features a hydroxyl group (-OH) at the 4-position of the cyclophosphamide structure, which enhances its reactivity and therapeutic efficacy. 4-Hydroxycyclophosphamide is known for its ability to form DNA cross-links, leading to the inhibition of DNA synthesis and ultimately inducing apoptosis in rapidly dividing cancer cells. This compound is typically administered in a clinical setting for the treatment of various malignancies, including lymphomas and solid tumors. Its pharmacokinetics involve conversion to other active metabolites, and it is important to monitor for potential side effects, such as myelosuppression and bladder toxicity. The compound is also studied for its role in immunosuppressive therapies. As with many chemotherapeutic agents, careful dosing and patient management are crucial to maximize therapeutic benefits while minimizing adverse effects.

4-Hydroxycyclophosphamide

40277-05-2: 2-[Bis(2-chloroethyl)amino]-4-hydroxy-1,3,2λ5-oxazaphosphinan-2-one, 2-[Bis(2-chloroethyl)amino]tetrahydro-4-hydroxy-2H-1,3,2-oxazaphosphorine 2-oxide, 2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)-4-hydroxytetrahydro-, 2-oxide, 2H-1,3,2-oxazaphosphorin-4-ol, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, 4-Hydroxycyclophosphamide, Asta 6635, NSC 196562

This compound is a phosphoramidate analog of cyclophosphamide. It has been shown to have an effect on the glomerular filtration rate and to inhibit DNA, RNA, and protein synthesis in human cells. The compound binds to the dinucleotide phosphate (NDP) site of the enzyme polymerase chain reaction (PCR) with high affinity, and inhibits DNA synthesis by competing with ATP. This active form is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. The kinetics of this drug have been studied using a concentration-time curve on human serum samples. The matrix effect can be avoided by preparing samples for analysis in a liquid phase instead of a solid phase. The analytical method for this drug has been developed in heart tissue preparations from rats treated with this drug at

CAS 40277-05-2: 4-Hydroxycyclophosphamide

2-(Bis(2-chloroethyl)amino)-4-hydroxy-1,3,2-oxazaphosphinane 2-oxide

Ref: 3D-FB175219

4-Hydroxy Cyclophosphamide

Ref: 4Z-C-1022